Welcome to the Onyx Pharmaceuticals Conference Call. My name is Ellen, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this
Morningstar generic- pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.
Associate director for health-care analysis Alex Morozov on the uncertainty-overhang relief, biggest winners, and best values in post-reform health care.